N6‑methyladenosine methyltransferase METTL14 is associated with macrophage polarization in rheumatoid arthritis

Ziheng Zhu1, Lei Wan1,2

  • 1Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230031, P.R. China.

Insights

Methyltransferase 14 (METTL14) is elevated in rheumatoid arthritis (RA) patients, correlating with disease severity and inflammation. METTL14 may worsen RA by promoting macrophage polarization through the MAPK pathway.

Area of Science:

  • Immunology
  • Epigenetics
  • Molecular Biology

Background:

  • Rheumatoid arthritis (RA) pathogenesis involves inflammatory responses driven by macrophage polarization.
  • N6-methyladenosine (m6A) RNA methylation is an epigenetic modification influencing macrophage polarization.
  • The precise role of m6A methylation in RA macrophage polarization remains unclear.

Purpose of the Study:

  • To investigate the function and mechanisms of m6A methylation, specifically Methyltransferase 14 (METTL14), in macrophage polarization within the context of RA.
  • To determine the correlation between METTL14 expression and RA clinical and inflammatory markers.

Main Methods:

  • Reverse-transcription quantitative PCR (RT-qPCR) to assess mRNA expression of m6A methylase genes and signaling pathway components.
  • Western blot analysis for METTL14 protein levels.
  • ELISA and flow cytometry for cellular secretion factors and macrophage markers (CD68+, CD86+).
  • Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.

Main Results:

  • Elevated METTL14 expression was observed in RA patients' peripheral blood and synovial tissue.
  • METTL14 levels positively correlated with C-reactive protein, rheumatoid factor, and pro-inflammatory cytokine TNF-α.
  • METTL14 expression was associated with M1 macrophage markers (CD68+, CD86+) and predicted visual analogue scale scores.
  • METTL14 was linked to the MAPK signaling pathway, with increased JNK and ERK2 expression in high METTL14 groups.

Conclusions:

  • METTL14 is upregulated in RA and associated with disease severity and inflammatory markers.
  • METTL14 may exacerbate RA by promoting macrophage polarization via the MAPK signaling pathway.
  • METTL14 represents a potential therapeutic target for managing RA-associated inflammation.